1Buy.AI | $3,900,000 | (Feb 3, 2026)
PranaX | $17,000,000 | (Feb 3, 2026)
DexMat | $5,000,000 | (Feb 3, 2026)
Receptor Life Sciences, Inc.
United States
- Seattle, Washington
- 07/04/2022
- Series A
- $9,700,000
Receptor Life Sciences combines proven drug delivery technologies, compelling therapeutic candidates, and traditional drug development research practices to pursue a robust range of prescription drug treatments for CNS indications.
The delivery technologies, used in both oral and inhaled FDA-approved prescription drug products, represent a validated, strategic approach to overcoming traditional challenges of cannabinoid medicine. Receptor’s patented product candidates hold the potential to provide prescription treatments for a range of unmet medical needs, including anxiety and agitation in autism.
More information is at www.ReceptorLife.com.
- Industry Pharmaceutical Manufacturing
- Website https://receptorlife.com/
- LinkedIn https://www.linkedin.com/company/receptor-life-sciences-inc./
Related People
Mark TheeuwesFounder
United States -
Greater Philadelphia
Experienced Pharmaceutical Executive with a demonstrated history of working in all aspects of Clinical and Commercial Execution.
Prenosis | $20,000,000 | (Feb 3, 2026)
CloudForge AI | $3,950,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
Poetiq | $45,800,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)
Principle | $2,000,000 | (Feb 3, 2026)
BizTrip AI | $1,500,000 | (Feb 3, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)